Early trial tests 'Living Drug' for aggressive blood cancer
NCT ID NCT05654779
Summary
This early-stage study tested a new type of treatment called LCAR-AMDR, a CAR-T cell therapy, for adults and teens with acute myeloid leukemia (AML) that has come back or hasn't responded to standard treatments. The main goals were to find a safe dose and see if the therapy could help control the cancer. The study was small and ended early, so results are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Gobroad BoRen Hospital
Beijing, Beijing Municipality, 100070, China
-
Chinese Academy of Medical Science and Blood Disease Hospital
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.